Clinical trial
Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell…
NCT00422786 · Thallion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00422786 |
|---|---|
| Title | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma |
| Official title | A Multi-Centre, Open Label, Phase II Study of the Safety, Efficacy and Pharmacokinetic (PK) Profile of CAP-232 Administered Through Continuous Intravenous Infusion in Patients With Metastatic Kidney Cancer |
| Lead sponsor | Thallion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | CAP-232 |
| Enrollment | 10 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 17, 2007 |
| Last update posted | Jul 15, 2008 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: